<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190528</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG0102</org_study_id>
    <secondary_id>C000000194</secondary_id>
    <nct_id>NCT00190528</nct_id>
  </id_info>
  <brief_title>A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer</brief_title>
  <official_title>Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Bulky Stage I/II Cervical Cancer: Japan Clinical Oncology Group Trial (JCOG0102)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haruhiko Fukuda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <brief_summary>
    <textblock>
      To investigate the clinical benefits of neoadjuvant chemotherapy for bulky stage I/II&#xD;
      cervical cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed this randomized study to investigate the clinical benefits of neoadjuvant&#xD;
      chemotherapy for bulky stage I/II cervical cancer. Patients with FIGO stage I/II with bulky&#xD;
      disease are randomized to either neoadjuvant chemotherapy (BOMP: Cisplatin 14mg/m2 day 1-5,&#xD;
      Bleomycin 7mg day 1-5, Mitomycin 7mg/m2 day 5, and Vincristine 0.7mg/m2 day every 21 days for&#xD;
      2-4 cycles followed by radical hysterectomy or radical hysterectomy alone. The primary&#xD;
      endpoint is overall survival and the secondary endpoints are progression-free survival,&#xD;
      complication of surgery, completeness of radical hysterectomy, omission of postsurgical&#xD;
      irradiation, completeness of postsurgical irradiation, response rate, and adverse events. A&#xD;
      total 200 patients (100 per treatment arm) planned to accrue for this study within 5.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication of surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>completeness of radical hysterectomy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>omission of postsurgical irradiation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>completeness of postsurgical irradiation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant chemotherapy + radical hysterectomy</intervention_name>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical hysterectomy</intervention_name>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Untreated cervical cancer&#xD;
&#xD;
          2. Pathologically diagnosed squamous carcinoma&#xD;
&#xD;
          3. FIGO stage Ib2, IIa (&gt;4cm), and IIb&#xD;
&#xD;
          4. Measurable lesions&#xD;
&#xD;
          5. Possible to radical hysterectomy&#xD;
&#xD;
          6. Age: 20 to 70 years&#xD;
&#xD;
          7. PS: 0 and 1&#xD;
&#xD;
          8. WBC &gt; 3,000/mm3, Hb &gt; 9.0g/dl, Platelet &gt; 100,000 /mm3, SGOT/SGPT &lt; 60 IU/L, T-Bil &lt;&#xD;
             1.5 mg/dL, Cr &lt; 1.2 mg/dL, PaO2 &gt; 80 torr, normal ECG&#xD;
&#xD;
          9. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have any evidence of the other cancer present within the last 5 years&#xD;
             with the exception of carcinoma in situ or intramucosal cancer those are curable with&#xD;
             local therapy&#xD;
&#xD;
          2. Women during pregnancy or breast-feeding&#xD;
&#xD;
          3. Patients with psychiatric illness&#xD;
&#xD;
          4. Patients who have active infection&#xD;
&#xD;
          5. Patients who have uncontrolled diabetes or uncontrolled hypertension&#xD;
&#xD;
          6. Patients who have positive HBs&#xD;
&#xD;
          7. Patients who have had heart failure, unstable angina, or myocardial infarction within&#xD;
             the past 6 months&#xD;
&#xD;
          8. Patients with interstitial pneumonitis or pulmonary fibrosis&#xD;
&#xD;
          9. Patients who are unable to undergo radical hysterectomy for complication of excessive&#xD;
             obesity, liver cirrhosis, or bleeding tendency&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiharu Kamura, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kurume University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Japan Clinical Oncology Group</investigator_affiliation>
    <investigator_full_name>Haruhiko Fukuda</investigator_full_name>
    <investigator_title>JCOG Data Center</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>drug therapy</keyword>
  <keyword>cisplatin</keyword>
  <keyword>bleomycin</keyword>
  <keyword>mitomycin</keyword>
  <keyword>vincristine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

